Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory drug presented as an oral tablet for oral use. It treats certain blood cancers, notably multiple myeloma and myelodysplastic syndromes with del(5q), in adult patients. GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomid Zentiva is indicated for hematologic malignancies that respond to immunomodulation.

- Multiple Myeloma: used as part of combination therapy to control disease progression in adult patients. - Myelodysplastic Syndromes with del(5q): improves blood counts and reduces transfusion dependence in adult patients. - Relapsed/Refractory Multiple Myeloma: employed after prior therapies to achieve disease control.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Lenalidomid Zentiva requires careful monitoring and specific safety measures.

- Pregnancy contraindication: drug is Category X and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation when appropriate. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Infection vigilance: monitor for signs of infection and manage promptly. - Drug interaction awareness: avoid concomitant use with strong CYP3A4 inhibitors. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomid Zentiva can interact with several medicines, requiring clinical attention.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Thalidomide: combined use adds teratogenic risk. - Pregnancy: drug is contraindicated and must be avoided.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness. - Anticoagulants: may enhance bleeding tendency. - Live vaccines: immune response may be diminished, requiring caution.